2,523 Shares in Cardinal Health, Inc. $CAH Acquired by Patron Partners LLC

Patron Partners LLC bought a new stake in shares of Cardinal Health, Inc. (NYSE:CAH) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,523 shares of the company’s stock, valued at approximately $599,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CAH. OneAscent Financial Services LLC purchased a new position in Cardinal Health in the 2nd quarter worth approximately $511,000. Paralel Advisors LLC purchased a new stake in shares of Cardinal Health during the 2nd quarter valued at $2,597,000. Allworth Financial LP bought a new stake in shares of Cardinal Health during the 2nd quarter worth $1,095,000. B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Cardinal Health during the 2nd quarter worth $6,317,000. Finally, Silvant Capital Management LLC purchased a new position in Cardinal Health in the second quarter worth $223,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health Stock Performance

CAH stock opened at $229.48 on Friday. The firm has a market cap of $53.37 billion, a P/E ratio of 31.74, a P/E/G ratio of 1.22 and a beta of 0.49. The firm’s fifty day moving average is $232.02 and its 200 day moving average is $217.86. Cardinal Health, Inc. has a 52 week low of $145.87 and a 52 week high of $258.30.

Cardinal Health (NYSE:CAH) last posted its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $63.67 billion during the quarter, compared to the consensus estimate of $65.15 billion. During the same period in the previous year, the firm posted $2.08 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, analysts forecast that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a $0.5158 dividend. This represents a $2.06 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, October 1st. Cardinal Health’s payout ratio is 28.49%.

Insider Buying and Selling

In related news, CAO Mary C. Scherer sold 2,302 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $237.39, for a total transaction of $546,471.78. Following the completion of the sale, the chief accounting officer directly owned 2,811 shares in the company, valued at $667,303.29. This represents a 45.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jason M. Hollar sold 44,529 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $236.18, for a total value of $10,516,859.22. Following the transaction, the chief executive officer owned 190,603 shares in the company, valued at approximately $45,016,616.54. The trade was a 18.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 210,271 shares of company stock worth $49,626,657 in the last 90 days. 0.12% of the stock is currently owned by company insiders.

Key Stories Impacting Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Wall Street Analyst Weigh In

CAH has been the topic of a number of research analyst reports. Robert W. Baird increased their target price on Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Morgan Stanley upped their price objective on Cardinal Health from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. UBS Group increased their price objective on Cardinal Health from $274.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Mizuho raised their price objective on Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Finally, Leerink Partners set a $292.00 target price on Cardinal Health in a research report on Tuesday, August 11th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Cardinal Health currently has an average rating of “Moderate Buy” and a consensus price target of $266.56.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.